Inotiv, Inc.

Equities

NOTV

US45783Q1004

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
8.95 USD -1.97% Intraday chart for Inotiv, Inc. +17.30% +143.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Stock Futures -2- DJ
Jefferies Upgrades Inotiv to Buy Rating From Hold, Adjusts Price Target to $11.50 From $3 MT
Inotiv, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023 CI
Transcript : Inotiv, Inc., Q1 2024 Earnings Call, Feb 07, 2024
Earnings Flash (NOTV) INOTIV Reports Q1 Revenue $135.5M, vs. Street Est of $132.9M MT
Inotiv, Inc. Reaffirms Earnings Guidance for the Fiscal 2024 CI
An unknown buyer acquired RMS facilities in Spain and France from Inotiv, Inc.. CI
Jefferies Adjusts Inotiv Price Target to $3 From $7.25, Maintains Hold Rating MT
Craig-Hallum Adjusts Price Target on Inotiv to $25 From $34, Maintains Buy Rating MT
Inotiv Q4 Loss Narrows, Revenue Falls; Issues Fiscal 2024 Guidance -- Shares Rise After Hours MT
Inotiv, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023 CI
Earnings Flash (NOTV) INOTIV Reports Q4 Revenue $140.7M, vs. Street Est of $139.4M MT
Inotiv, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023 CI
Inotiv, Inc. Provides Earnings Guidance for the Fiscal Year 2024 CI
Transcript : Inotiv, Inc., Q4 2023 Earnings Call, Dec 11, 2023
Inotiv Guides For FY 2024 Revenue of $580-$590 Million, vs CIQ Analyst Consensus of $583 Million MT
Running the central bank gauntlet RE
North American Morning Briefing : Investors Await -2- DJ
Inotiv Unveils Partnership to Support Integration of North American Transportation Operations MT
Inotiv, Inc. Announces Changes to Its Board Composition CI
Inotiv Closes Sale of Israeli Businesses to Harlan Holdings MT
Harlan Holdings Ltd. acquired Israeli Businesses from Inotiv, Inc. for $3.7 million. CI
Health Care Limits Losses on Obesity-Drug Hopes -- Health Care Roundup DJ
Transcript : Inotiv, Inc., Q3 2023 Earnings Call, Aug 10, 2023
Earnings Flash (NOTV) INOTIV Reports Q3 Revenue $157.5M, vs. Street Est of $151.1M MT
Chart Inotiv, Inc.
More charts
Inotiv, Inc. is an international contract research company that is providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Its DSA segment supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Its RMS segment offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.95 USD
Average target price
18.25 USD
Spread / Average Target
+103.91%
Consensus
  1. Stock
  2. Equities
  3. Stock Inotiv, Inc. - Nasdaq
  4. News Inotiv, Inc.
  5. Inotiv : Acquires Gateway Pharmacology Labs, Adding to Its Drug Metabolism, Pharmacokinetics Testing Capabilities